



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Dofequidar

Item No. 30925

CAS Registry No.: 129716-58-1  
Formal Name: 1-[4-[2-hydroxy-3-(5-quinolinylloxy)propyl]-1-piperazinyl]-2,2-diphenyl-ethanone  
MF:  $C_{30}H_{31}N_3O_3$   
FW: 481.6  
Purity:  $\geq 98\%$   
Supplied as: A solid  
Storage:  $-20^{\circ}\text{C}$   
Stability:  $\geq 3$  years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Dofequidar is supplied as a solid. A stock solution may be made by dissolving the dofequidar in the solvent of choice, which should be purged with an inert gas. Dofequidar is soluble in the organic solvent DMSO.

### Description

Dofequidar is a quinoline derivative and inhibitor of multidrug resistance.<sup>1,2</sup> It inhibits P-glycoprotein in a photolabeling assay when used at a concentration of 100  $\mu\text{M}$ .<sup>1</sup> Dofequidar (10  $\mu\text{M}$ ) increases intracellular accumulation of [ $^3\text{H}$ ]-vincristine in HL-60R cells endogenously expressing the gene encoding multidrug resistance-associated protein (MRP).<sup>2</sup> It restores susceptibility to vincristine- or doxorubicin-induced cytotoxicity in vincristine-resistant P388, vincristine-resistant K562, and doxorubicin-resistant K562 cells in a concentration-dependent manner.<sup>1</sup> Dofequidar (80 mg/kg twice per day) increases survival in a vincristine-resistant P388 murine leukemia model compared with untreated controls when administered in combination with vincristine (Item No. 11764).

### References

1. Sato, W., Fukazawa, N., Nakanishi, O., *et al.* Reversal of multidrug resistance by a novel quinoline derivative, MS-209. *Cancer Chemother. Pharmacol.* **35**(4), 271-277 (1995).
2. Narasaki, F., Oka, M., Fukuda, M., *et al.* A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. *Cancer Chemother. Pharmacol.* **40**(5), 425-432 (1997).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/03/2020

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897  
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM